BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

Core Insights - BioCryst Pharmaceuticals reported a strong Q1 2025 performance with ORLADEYO net revenue of $134.2 million, reflecting a 51% year-over-year increase [1][6] - The company has raised its full-year 2025 revenue guidance for ORLADEYO to between $580 million and $600 million, up from previous estimates [1][15] - BioCryst anticipates achieving profitability for the full year 2025, a year earlier than previously expected [1][16] Financial Performance - Total revenues for Q1 2025 reached $145.5 million, a 56.8% increase from $92.8 million in Q1 2024 [8] - Research and development expenses decreased to $37.3 million, down 19.8% from $46.5 million in Q1 2024 [9] - Selling, general and administrative expenses rose to $82.5 million, a 38.7% increase compared to $59.5 million in Q1 2024 [10] - Operating income for Q1 2025 was $21.2 million, compared to an operating loss of $14.5 million in Q1 2024 [11] Debt Management - The company paid down $75 million of its debt early in Q2 2025, which is expected to save approximately $23.5 million in interest over the loan's life [1][14] Product Development - BioCryst submitted a new drug application (NDA) for ORLADEYO oral granules for children aged 2-11 with hereditary angioedema (HAE) [1][5] - The company is progressing with clinical trials for BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema (DME) [7][11] Market Dynamics - The percentage of ORLADEYO patients on paid drug increased to approximately 84%, up from 73.5% at the end of 2024, indicating strong market demand [6][4] - A recent survey indicated that 70% of U.S. HAE patients prefer oral prophylaxis therapy, up from 50% in 2023 [6]